HomeCompareSFE vs MRK

SFE vs MRK: Dividend Comparison 2026

SFE yields 76.92% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SFE wins by $1.39M in total portfolio value
10 years
SFE
SFE
● Live price
76.92%
Share price
$0.46
Annual div
$0.35
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.45M
Annual income
$406,212.55
Full SFE calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SFE vs MRK

📍 SFE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSFEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SFE + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SFE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SFE
Annual income on $10K today (after 15% tax)
$6,538.46/yr
After 10yr DRIP, annual income (after tax)
$345,280.67/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SFE beats the other by $336,952.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SFE + MRK for your $10,000?

SFE: 50%MRK: 50%
100% MRK50/50100% SFE
Portfolio after 10yr
$750.9K
Annual income
$208,005.34/yr
Blended yield
27.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SFE
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-43.5
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SFE buys
0
MRK buys
0
PoliticianChamberTickerTypeAmountDate
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-02-02
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-02-02
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-26
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-26
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-22
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-22
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-20
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-20
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-19
Michael McCaul🏢 House$SFE▼ Sell$1,001 - $15,0002021-01-19
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSFEMRK
Forward yield76.92%2.76%
Annual dividend / share$0.35$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$1.45M$56.8K
Annual income after 10y$406,212.55$9,798.13
Total dividends collected$1.25M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: SFE vs MRK ($10,000, DRIP)

YearSFE PortfolioSFE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$18,392$7,692.31$11,206$366.19+$7.2KSFE
2$32,902$13,222.36$12,650$502.35+$20.3KSFE
3$57,311$22,106.15$14,407$694.19+$42.9KSFE
4$97,310$35,987.08$16,585$967.82+$80.7KSFE
5$161,228$57,105.82$19,342$1,363.89+$141.9KSFE
6$260,939$88,425.56$22,913$1,947.19+$238.0KSFE
7$412,955$133,749.94$27,662$2,823.89+$385.3KSFE
8$639,683$197,821.28$34,159$4,173.35+$605.5KSFE
9$970,847$286,385.73$43,337$6,308.80+$927.5KSFE
10$1,445,019$406,212.55$56,776$9,798.13+$1.39MSFE

SFE vs MRK: Complete Analysis 2026

SFEStock

Safeguard Scientifics, Inc. no longer investing. It is a private equity and venture capital firm specializing in expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, growth stage, and early stage financings. It initially invests in a Series A-C round and opportunistically in a seed round. The firm prefers to make investments in companies engaged in the technology, financial services, and healthcare sector. Within the technology sector, it invests in software as a service, adtech / digital media, Internet of Everything, enhanced security, predictive analytics, machine learning, artificial intelligence, enterprise software, technology enabled services, internet/new media, financial technology, cloud, mobile, social, big data, in memory, and selected business services with capital requirements of up to $25 million. Within healthcare sector, the firm invests in molecular and point-of-care diagnostics, medical devices, regenerative medicine, medical technology, digital health, healthcare technology, specialty pharmaceuticals, and selected healthcare services. It invests throughout the United States with a focus on Mid-Atlantic region, and Southeastern Canada. The firm primarily invests between $5 million and $25 million in growth equity financing and between $5 million and $10 million in early-stage financing. It typically invests in the capital structures including owner financed and bootstrapped companies, corporate division or business unit, and venture capital-backed seeking a growth partner. The firm prefers to be the largest shareholder in its portfolio companies, with ownership in the range of 20 percent to 50 percent. However, it may occasionally take a majority or smaller stake in its portfolio companies. It prefers to invest in companies having proprietary technology and intellectual property. The firm prefers to take a Board seat in its portfolio companies. The company was founded in 1953 as Lancaster Corporation and changed its name to Safeguard Scientifics, Inc. in 1981. Safeguard Scientifics, Inc. is based in Radnor, Pennsylvania with additional office in Weston, Massachusetts.

Full SFE Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SFE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SFE vs SCHDSFE vs JEPISFE vs OSFE vs KOSFE vs MAINSFE vs JNJSFE vs ABBVSFE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.